# $120M Alert: Another significant funding round in AI-driven drug discovery, this time with Lilly...

> Another significant $120M funding round has landed in AI-driven drug discovery, this time with Lilly leading alongside Nvidia and key VC funds. I'm optimistic that we could be witnessing the birth of the next Amgen, Genentech, or Biogen — powered by AI.

URL: https://www.ch-healthtech.com/insights/120m-alert-another-significant-funding-round-ai-driven-drug-discovery-time-lilly
Markdown: https://www.ch-healthtech.com/insights/120m-alert-another-significant-funding-round-ai-driven-drug-discovery-time-lilly.md
Published: 2024-09-10
Updated: 2026-05-06
Author: Christian Hein
Tags: technology/artificial-intelligence, industry/biotech, industry/tech-bio, activity/venture-investment, function/innovation-management, function/strategic-planning, function/pre-clinical-research

---


$120M Alert: Another significant funding round in AI-driven drug discovery, this time with Lilly leading the way!

The surge in investments for AI-enabled biotech and techbio companies continues strong. Recent rounds include Formation Bio, Xaira Therapeutics, and now, Lilly - alongside Nvidia and key VC funds - investing $120M into a company focused on GPCR targets, leveraging a fully virtual screening approach.

Despite challenges faced by companies like Recursion, I believe this is just the beginning. We might be witnessing the birth of the next Amgen, Genentech, or Biogen - the giants that emerged from the molecular biology revolution. Could AI be the driving force behind the next wave of biopharma innovation? I'm optimistic.

https://lnkd.in/eAE3GNem